Why I would buy these top healthcare shares today

The healthcare sector was one of the better performing areas of the market last year and I expect it to be similarly strong again this year due to the quality companies within it.

Two healthcare shares which I think would be great options for investors today are listed below. Here’s why I like them:

CSL Limited (ASX: CSL)

Despite the fact that this biotherapeutics company’s shares beat the market last year with a 41% return, I still believe they have the potential to outperform the market again this year due to the strong performance of its leading immunoglobulin business and soon to be profitable Seqirus vaccine business.

Ultimately, I believe these businesses and the strong underlying demand it is experiencing has put the company in a position to deliver above-average long-term profit growth. I’m not alone in thinking this. A broker note out of Credit Suisse in December revealed that the broker had an outperform rating and $155 price target on CSL’s shares.

Ramsay Health Care Limited (ASX: RHC)

Although 2017 was a bit of a disappointment for this leading private hospital operator Ramsay, I think its recent share price weakness has left its shares trading at a very attractive price for a buy and hold investment. Due to ageing populations and increased chronic disease, I expect Ramsay to deliver above-average organic earnings growth for at least the next decade.

Furthermore, due to its strong balance sheet I believe Ramsay has the option to accelerate its growth inorganically through expansions and acquisitions. While the same tailwinds should also be a boost for rival Healthscope Ltd (ASX: HSO), I think the quality of its hospitals, its global footprint, and experienced management team make Ramsay the better pick.

As well as CSL and Ramsay, I think these growing blue chip shares would be great investments this year.

Top 3 ASX Blue Chips To Buy In 2018

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2018."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ramsay Health Care Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The 5 mining stocks we’re recommending in 2019…

For decades, Australian mining companies have minted money for individual investors like you and me. But if you believe the pundits and talking heads on TV, those days are long gone. Finito! Behind us forever…

We say nothing could be further from the truth. To earn the really massive returns, you’ve got to fish where others aren’t fishing—and the mining sector could be primed for a resurgence. That’s why top Motley Fool analysts just revealed their exciting new research on 5 ASX miners they believe could help you profit in 2019 and beyond…


The best way we see to play the global zinc shortage… Our #1 favourite large-cap miner (hint: it’s not BHP)… one early-stage gold miner we think could hit the motherlode… Plus two more surprising companies you probably haven’t heard of yet!

For free access to our brand-new research, simply click here or the link below. But be warned, this research is available free for a limited time only, and we reserve the right to withdraw it at any time.

Click here for your FREE report!